Pharmaceuticals

Driving Growth In The Peanut Allergy Treatment Market Through Research And Development Investment Is Supporting Development Across The Peanut Allergy Treatment Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Peanut Allergy Treatment Market During The Forecast Period?

The peanut allergy treatment market has expanded considerably in recent years. Its valuation is anticipated to increase from $0.5 billion in 2025 to $0.55 billion in 2026, progressing at a compound annual growth rate (CAGR) of 10.8%. This historical expansion can be attributed to the rising incidence of peanut allergies in children, the constrained efficacy of avoidance-only management strategies, a surge in the diagnosis of food allergies, a strong reliance on epinephrine for urgent care, and enhanced awareness among medical professionals.

The peanut allergy treatment market is projected to experience substantial expansion in the coming years, anticipated to reach a value of $0.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.7%. This projected growth during the forecast period is driven by several factors, including advancements in immunotherapy technologies, a rise in approvals for disease-modifying treatments, increasing demand for preventive allergy care, the broadening scope of biologics aimed at allergic pathways, and a surge in investment for food allergy research. Key trends expected over the forecast horizon encompass the increasing uptake of oral immunotherapy for peanut desensitization, the expanding application of epicutaneous immunotherapy patches, enhanced incorporation of biologic therapies within allergy treatment protocols, the development of more pediatric-specific peanut allergy interventions, and a stronger focus on solutions for sustained allergy management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

Which Drivers Are Advancing The Peanut Allergy Treatment Market Growth?

The investment in research and development for allergy treatments is projected to drive the growth of the peanut allergy treatment market in the future. Research and development (R&D) investment refers to the financial resources allocated by companies, organizations, or governments towards activities aimed at innovation, product development, and technological advancement. This investment in R&D for allergy treatments is crucial for advancing peanut allergy therapies, as it fosters the creation of innovative immunotherapies and desensitization techniques. These innovations aim to reduce allergic reactions and improve the quality of life for those affected by peanut allergies. For instance, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, to significantly advance global peanut allergy treatment. This funding forms part of a broader $66 million round intended for developing Aravax’s innovative immunotherapy, PVX108. This initiative has secured Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), underscoring its potential worldwide impact on public health. Therefore, investment in the research and development of allergy treatments is propelling the growth of the peanut allergy treatment market.

What Are The Major Segment Categories Within The Peanut Allergy Treatment Market?

The peanut allergy treatment market covered in this report is segmented –

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes

2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:

1) By Antihistamines: Oral Antihistamines, Topical Antihistamines

2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)

3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers

4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

What Trends Are Influencing The Peanut Allergy Treatment Market Outlook?

Leading companies in the peanut allergy treatment market are concentrating on developing biologic therapies, such as anti-IgE monoclonal antibodies, to provide more targeted and effective options for managing peanut allergies, thereby enhancing patient outcomes and their quality of life. Anti-IgE monoclonal antibodies are a type of therapeutic agent specifically designed to target and neutralize immunoglobulin E (IgE) antibodies in the body. For instance, in February 2024, Novartis Pharmaceuticals Corporation, a Switzerland-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Xolair (omalizumab). This medication is intended to alleviate allergic reactions, including anaphylaxis, in patients aged 1 year and older with IgE-mediated food allergies. The approval was supported by data from the NIH-sponsored Phase III OUtMATCH study, which demonstrated significant improvement in food allergy tolerance among patients treated with Xolair compared to those who received a placebo.

Which Key Players Are Active In The Peanut Allergy Treatment Market?

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

Access The Complete Peanut Allergy Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

Which Region Leads The Peanut Allergy Treatment Market By Size?

North America was the largest region in the peanut allergy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Peanut Allergy Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

Browse Through More Reports Similar to the Global Peanut Allergy Treatment Market 2026, By The Business Research Company

Peanut Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-treatment-global-market-report

Food Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/food-allergy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795